PRESS-RELEASE ·Filed Mar 2, 2026
Press release · Earnings
Actionable Insight • Neutral
Traders should monitor the upcoming earnings call for updates on clinical progress, cash runway, and R&D spending, which could impact sentiment given Allogene's clinical-stage, cash-burning profile.
Final — all horizons settled through T+60d
ALLO ▼ -20.00% at T+60d
NEUTRAL call -20.00% · α vs SPY -29.33% · entry $2.65 → $2.12
T+1d
-4.53%
call -4.53% · α -3.61%
$2.53
settled 8mo ago
T+5d
-5.66%
call -5.66% · α -4.45%
$2.50
settled 8mo ago
T+20d
-16.23%
call -16.23% · α -8.29%
$2.22
settled 7mo ago
T+60d
-20.00%
call -20.00% · α -29.33%
$2.12
settled 5mo ago
Price Chart
Loading chart...
Executive Summary
Allogene Therapeutics announced it will report its fourth quarter and full year 2025 financial results on March 12, 2026, followed by a conference call. The press release contains no actual financial data, only logistical details for the earnings announcement.
Key Facts
- Allogene Therapeutics will report Q4 and full year 2025 financial results on March 12, 2026, after market close.
- A conference call and webcast are scheduled for the same day at 2:00 p.m. PT / 5:00 p.m. ET.
- No financial results or business updates were disclosed in this press release.
- The company is in the clinical stage and developing allogeneic CAR T therapies for cancer and autoimmune diseases.
Financial Impact
No financial data disclosed
Risk Factors
- High R&D burn rate typical of clinical-stage biotechs with no approved products.
- Forward-looking statements are subject to significant risks including regulatory delays, clinical trial failures, and funding needs.
Market Snapshot
Exchange
Nasdaq
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3247392 |
23 reports for ALLO
73% Hit rate @ T+1 Went positive at some point 10 of 11 best @ T+20▲ +19.14%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G/A | $1.21 | awaiting T+1 | — | $1.23 (+1.65%) |
Oct 21, 2026 5d ago | 144 | $1.25 $1.25 | · 0.00% | ▲ +0.52% | $1.23 (−1.60%) |
Sep 2, 2026 7w ago | 8-K | $1.98 $1.98 | · 0.00% | ▼ −1.05% | $1.23 (−37.88%) |
Aug 21, 2026 9w ago | 144 | $2.03 $2.17 | ▲ +6.90% | ▲ +6.58% | $1.23 (−39.41%) |
Aug 21, 2026 9w ago | EFFECT | $2.09 $2.03 | ▲ +2.87% | ▲ +2.58% | $1.23 (+41.15%) |
Aug 6, 2026 11w ago | Institutional Cluster | $1.97 $2.01 | ▲ +2.03% | ▲ +1.42% | $1.23 (−37.56%) |
Jun 22, 2026 18w ago | 8-K | $2.07 $2.05 | ▲ +0.97% | ▲ +0.92% | $1.23 (+40.58%) |
Jun 22, 2026 18w ago | 424B5 | $2.07 $2.05 | ▲ +0.97% | ▲ +0.92% | $1.23 (+40.58%) |
May 28, 2026 21w ago | DEFA14A | $2.17 $2.15 | ▼ −0.92% | ▼ −1.18% | $1.23 (−43.32%) |
May 28, 2026 21w ago | 8-K | $2.17 $2.15 | ▼ −0.92% | ▼ −1.18% | $1.23 (−43.32%) |
Showing 10 of 23
US Market Status
Market Closed — Opens Wed (15h 41m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers